Get the Stockscreener App
12.68
2.46%
-0.32
Rapport Therapeutics Inc stock is traded at $12.68, with a volume of 154.93K.
It is down -2.46% in the last 24 hours and down -4.45% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$13.00
Open:
$13.21
24h Volume:
154.93K
Relative Volume:
1.40
Market Cap:
$463.79M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-20.25%
1M Performance:
-4.45%
6M Performance:
-43.57%
1Y Performance:
+0.00%
1-Day Range:
$12.50
$13.24
1-Week Range:
$12.50
$16.04
52-Week Range:
$12.09
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
12.68 | 463.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat
JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat
J&J-backed Rapport Therapeutics files for $100M IPO - MSN
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(RAPP) Proactive Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World
‘A really rational IPO environment’: What does it takes for a biotech to go public now? - Fierce Biotech
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's ... - The Bakersfield Californian
Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week LowHere's What Happened - MarketBeat
Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
58,046 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by State Street Corp - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4%Here's Why - MarketBeat
Learn to Evaluate (RAPP) using the Charts - Stock Traders Daily
TARPγ8 negative allosteric modulators as new approach for epilepsy - BioWorld Online
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
Shareholder Alert: Ademi LLP investigates whether Nordstrom, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
LTRPA, LTRPB Investors Have the Opportunity to Join Investigation of Liberty TripAdvisor Holdings, Inc. with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
The Manitowoc Company reaches agreement to settle U.S. EPA matter regarding its emissions certification and compliance process - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director |
Jun 10 '24 |
Buy |
17.00 |
558,824 |
9,500,008 |
1,863,327 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):